Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934568 · ClinicalTrials.gov registry record · Phase 2
Ribociclib (LEE011) Rollover Study for Continued Access
A Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 13
- Study locations
NCT02934568: Active Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies, sponsored by Novartis Pharmaceuticals.
NCT02934568 is a Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02934568, a Phase 2 study of Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.
Primary Outcome
Continued access to study treatment as a single agent or in combination with other investigational treatments until patients discontinue study
Conditions Studied
Interventions
- DRUG LEE011
Study Locations (13)
Other
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Tainan
- Novartis Investigative Site - Taipei
Alabama
- University Of Alabama At Birmingham - Birmingham
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- The Regents of the Uni of Michigan - Ann Arbor
New York
- Broome Oncology - Johnson City
Tennessee
- St Jude Childrens Research Hospital - Memphis
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
What the registry record for NCT02934568 still lists
NCT02934568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which LEE011 is the first listed.
NCT02934568 lists 13 locations in 7 states (Other, Alabama, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02934568 about?
NCT02934568 is a clinical study titled "Ribociclib (LEE011) Rollover Study for Continued Access". This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for othe...
What is the current status of trial NCT02934568?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-12-15. Estimated completion is 2027-02-01.
What conditions does trial NCT02934568 study?
This clinical trial studies the following conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies.
What interventions are being tested in trial NCT02934568?
The interventions under investigation include: LEE011 (DRUG).
Who is sponsoring clinical trial NCT02934568?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02934568 being conducted?
This trial has 13 study locations across Alabama, Massachusetts, Michigan, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02934568's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI